News

The efficacy of nivolumab, as investigated in an interim analysis of the NORA study was confirmed as treatment of patients with advanced renal cell carcinoma who received 2 more prior lines of therapy.

"We believe that poziotinib is a significant advancement for patients with this deadly disease in an area of high unmet medical need."

Second-line sunitinib demonstrated clinical activity after failure on frontline immunotherapy in patients with metastatic renal cell carcinoma.

In an interview with Targeted Oncology, David Reardon, MD, discussed the background and findings for the phase 1/2 clinical trial of INO-5401 and INO-9012 plus cemiplimab in patients with newly diagnosed glioblastoma.

The FDA has granted Fast Track designation to CMP-001 in combination with nivolumab plus ipilimumab under 2 melanoma indications.

“Given that the majority of the data analyzed in the study came from patients with relapsed/refractory disease, both autologous hematopoietic cell transplantation and allogeneic hematopoietic cell transplantation afford relatively high complete response rates when compared with established chemo-immunotherapy regimens and novel agents."

Irene Ghobrial, MD, discusses the importance of the data made available through the Multiple Myeloma Research Foundation’s CureCloud research study.

In an interview with Targeted Oncology, Bassel El-Rayes, MD, discussed the treatment options for patients with borderline resectable pancreatic cancer. He also discussed sequencing the available agents for borderline resectable pancreatic cancer and the role of circulating tumor DNA in guiding individualized treatment of the disease.

The FDA has granted an Orphan Drug designation to cobomarsen for the treatment of patients with T-cell lymphoma, according to an announcement from miRagen Therapeutics.

Targeted Oncology reviews trending news online for the week of July 24, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.

The FDA has approved brexucabtagene autoleucel for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

The expanded version of the BD Onclarity HPV Assay received approval for a pre-market approval supplement from the FDA, making it the only assay approved right now that individually identifies and reports human papillomavirus genotypes 31, 51, 52, 33/58, 35/39/68, and 56/59/66, as well as the standard 16,18, and 45.

A Biologics License Application has been submitted to the FDA for inolimomab as a potential treatment for adult patients with steroid-refractory acute graft-versus-host disease, grade II-IV,.

Data from a treatment utilization study revealed racial disparities in treatments as well as the effects and clinical outcomes of treatments such as remdesivir and dexamethasone in patients with cancer who were diagnosed with coronavirus disease 2019.

Avelumab in combination with a novel HPV16-targeted vaccine, demonstrated clinical activity as treatment of patients with HPV16-positive recurrent and/or metastatic malignancies.

Ruxolitinib demonstrated a superior overall response rate versus best available treatment at week 24 in patients with steroid-refractory or steroid-dependent chronic graft-versus-host-disease, according to topline results from the phase 3 REACH3 study.

In an interview with Targeted Oncology, following the tweet chat, Shoushtari highlighted the key takeaways from the tweet chat discussion and spoke to how he would make his own treatment decisions for this patient scenario.

In an interview with Targeted Oncology, Heinz-Josef Lenz, MD, PhD, discussed the history of immune checkpoint inhibition in the metastatic colorectal cancer treatment paradigm.

Ruxolitinib induced clinically meaningful reductions in both spleen size and symptoms for patients with myelofibrosis, including those with low platelet counts.

A pivotal phase 3 trial has been initiated to explore the combination of cabozantinib and atezolizumab for the treatment of patients with inoperable, locally advanced or metastatic renal cell carcinoma who progressed during or after treatment with an immune checkpoint inhibitor immediately following initial therapy.

In a presentation during the 2020 Debates and Didactics in Hematology and Oncology conference, Amelia A. Langston, MD, explained the issues with treating patients with relapsed mantle cell lymphoma and how the integration of chimeric antigen receptor T-cell therapy can be a solution to the problem.

The Association of Community Cancer Centers (ACCC) has partnered with the American Society of Clinical Oncology (ASCO) in a collaborative effort to improve the participation of racial and ethnic minority populations in cancer clinical trials.

Treatment with leronlimab in patients with mild to moderate symptoms of respiratory illness from coronavirus disease 2019 caused fewer serious adverse events when compared with placebo, according to safety results from a phase 2 clinical trial.

The risk of relapse or death was reduced by 61% with sorafenib maintenance compared with placebo following allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD–positive acute myeloid leukemia.

A 100% objective response rate was observed with CLR 131 as treatment of patients with relapsed/refractory lymphoplasmacytic lymphoma and Waldenström’s macroglobulinemia in the ongoing phase 2 CLOVER-1 study.

In an interview with Targeted Oncology, Delvys Rodriguez-Abreu, MD, discussed the findings from the KEYNOTE-189, which established the combination of pembrolizumab plus pemetrexed and platinum chemotherapy as the new standard of care for patients with metastatic nonsquamous non-small cell lung cancer.

The FDA cleared abivertinib to be investigated in a phase 2 clinical trial for the treatment of hospitalized patients with moderate to severe COVID-19.

A pathogenic germline mutation rate of about 5% has been identified in women who had a family history of breast or ovarian cancer but no personal history of either disease.

In an interview with Targeted Oncology, Srdan Verstovsek, MD, PhD, discussed the data from the MANIFEST trial, which evaluated the use of CPI-0610 as treatment of patients with myelofibrosis.